Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. - Wikidata - wikimedia - TriplyDB

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

http://www.wikidata.org/entity/Q33336807

about

Gemcitabine-based chemotherapy for advanced biliary tract carcinomas Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.Gallbladder Cancer in the 21st Century.Targeted therapy in biliary tract cancers-current limitations and potentials in the future.Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer EGFR expression in gallbladder carcinoma in North America.Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.Cholangiocarcinoma: modern advances in understanding a deadly old disease Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread.A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.Guidelines for chemotherapy of biliary tract and ampullary carcinomas Surgical strategy for bile duct cancer: Advances and current limitations.Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study.Current management of gallbladder carcinoma.Chemotherapy for advanced cholangiocarcinoma: what is standard treatment?Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.Phase II study of S-1 in patients with advanced biliary tract cancer.A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1.Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.Targeted therapy for biliary tract cancer.Adjuvant surgery for advanced extrahepatic cholangiocarcinoma.A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.A pathological complete response after combined chemotherapy of gemcitabine and S-1 in advanced biliary tract cancer with para-aortic lymph nodes metastasis: a case report.Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.Advances in the management of biliary tract cancers New and emerging treatment options for biliary tract cancer.

P2860

Q24187573-BE9BF26B-BFCD-486B-A6D8-173DC564EC23 Q24814067-8709C773-8524-417E-A9E4-F3F594394E12 Q26784174-02DF0B36-A7BF-4F6A-B20F-54439E7B7EDA Q30234532-C268F592-B6C6-42C6-BFFC-3EE6A8C3BF21 Q30300756-4C866632-F144-48DE-876C-47E2701BC867 Q33214444-3E5F22FE-972B-4CFC-B5CB-1DF4B6DA3F4F Q33360400-83AB4DBC-5E8B-4A80-AC0B-4C6326BA012A Q33368148-52EA25D7-FDCA-491A-AC5C-79201F416C23 Q33369276-D8B02F20-0B7A-4B0D-9AED-C478D87540BB Q33371325-ABAAEF2F-304C-4A37-9B7F-7B1BEB01BC57 Q33372640-11710EC5-ED56-4680-9144-5FE2BF2303F1 Q33372792-2868C4E0-1454-4410-A52C-B62BAFC675FF Q33375557-7C33715E-9971-403E-BF55-4635DA34B8B3 Q33391003-37922C3B-B64D-4B67-945B-5A94C8EA5408 Q33391729-C56ABC0E-9071-40FE-A36D-D9EFCB0737DC Q33399656-3A1483F5-80BC-4FD4-A056-F248B0C2F00C Q33430668-ED206A1E-9C4A-4C94-85DD-6253D16D2B83 Q33686690-83EB5340-225C-4185-8059-DF4EC2521E91 Q34000079-D6374910-F023-4DBB-BB7E-254110AA55A0 Q34018271-AEA8F4CD-EB9F-45D1-9D07-876848A65D8B Q34307050-7537BFBB-F446-4A07-BACD-DABD6E5AF950 Q34588361-5DF85D7B-56FD-40F1-BB41-9928D5CD8C3C Q34629377-C407B3E3-38DB-4CB6-A3D4-0C685C03B9C7 Q34999918-916BD9CE-774D-4E52-931A-16AFEA80E64E Q35583920-3B5387CE-76F3-4BA1-ACD2-EE102D71220C Q36572534-4CE29CDF-37E1-45F5-AF53-59AEFA596BA4 Q36614800-7FD0B000-0B6E-4254-9793-03D8862DE87F Q36624106-B57A3F4F-3E68-4DC0-8785-6BBFEB83DEED Q36688262-07BFB279-CAB9-4074-B9E2-75B6DFD9D599 Q36696249-69CB0088-355E-49F8-9E2C-C44A84D51A7B Q36868758-193776D0-9BE0-44DF-9406-3AAF212004D6 Q36962011-75D3DF4B-D6CE-4C6C-A9EA-AB64A71E34FF Q37132750-55A8E218-44D1-46E3-B3CF-56CD9275C3EA Q37266457-9AB7C539-8812-4D41-8963-CA84319636CC Q37413339-E27E9FD9-905F-4089-9001-B74BD6648861 Q37640354-C2C18699-166D-4D17-A053-17D36BD99681 Q37725603-5A73FD52-1155-478F-9633-1858B2CB7293 Q37817003-EFB84308-1D22-40ED-8232-4CF025D62AAE Q38082318-67A41C4B-66F4-4FCF-B29E-C226DCBC0AA3 Q38160836-01191793-37E4-4F32-9BF0-2F59C2BBF2D5

P2860

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

http://www.wikidata.org/entity/Q33336807

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@ast

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@en

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@nl

type

label

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@ast

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@en

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@nl

prefLabel

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@ast

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@en

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@nl

P1433

Q33336807-2CE5A254-4EBA-40B6-8B52-2F42C0C6AA5B

P1476

Q33336807-9F568AC7-ABCC-4871-9ADC-1D3611F71335

P2093

Q33336807-1134CBAC-2825-4B06-965A-AE6B0B9B034F

Q33336807-5C8DE7C0-E958-447E-BBF0-7DEF12B589AA

Q33336807-88E9BBDC-9FB1-46CA-BEF8-3EBDAEAEDCEF

Q33336807-890B36F5-A29E-41AD-A3F6-2A914E0DDB22

Q33336807-8B0E6760-02EF-46CA-8918-EED26B4537DE

Q33336807-8BB92269-9E8D-4688-BCBD-5F9FB391BAF7

Q33336807-922C6039-78DE-48EA-ABAB-FF80F31CBE8B

Q33336807-9CAF4D75-CE66-4484-BE50-C885EE7829A6

Q33336807-CF45CA7F-9170-4B5A-B4D4-5F15757D220D

Q33336807-DB06C02A-926E-4780-8F44-5EF38BE6EABE

P304

Q33336807-4D40E5A8-F1A5-45CE-AD61-EAFCEB3D84D2

P31

Q33336807-B2D429CC-2FA1-470A-8B3C-4DDE32890830

P356

Q33336807-4CFA331A-D34E-4AD0-A003-21C6A6DE1348

P433

Q33336807-E0C6F3AB-69E0-47E0-B807-54F5D1243F4D

P478

Q33336807-59F3A00B-86E0-4591-AF9D-0F8A0D98BA36

P577

Q33336807-808EFAE9-6F49-4603-8E1E-3933A36C407D

P698

Q33336807-32C80D8B-74C9-4EFD-A30A-73F4CA69856A

P921

Q33336807-B30DE72B-623E-43C6-A531-5CF0ACC45758

Q33336807-B52E668C-C810-49F6-A1D8-69976D390ADB

P356

A:1008352123009

P1433

Annals of Oncology

P1476

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

@en

P2093

A Lenauer

http://www.w3.org/2001/XMLSchema#string

B Schneeweiss

http://www.w3.org/2001/XMLSchema#string

D Depisch

http://www.w3.org/2001/XMLSchema#string

G Krauss

http://www.w3.org/2001/XMLSchema#string

G V Kornek

http://www.w3.org/2001/XMLSchema#string

H Ulrich-Pur

http://www.w3.org/2001/XMLSchema#string

M Penz

http://www.w3.org/2001/XMLSchema#string

M Raderer

http://www.w3.org/2001/XMLSchema#string

W Fiebiger

http://www.w3.org/2001/XMLSchema#string

W Scheithauer

http://www.w3.org/2001/XMLSchema#string

P304

183-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1008352123009

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11300321

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial